Displaying 1–19 of 19 results for Emil W. Ciurczak, Cadrai Technology Group
The DQ is a critical, yet often overlooked part of the process of developing and validating any new pharmaceutical PAT process. It is a strategically important time, where process engineers, material scientists and physical chemists can get together to develop meaningful materials ...
PAT expert Emil Ciurczak points out that a repository of methods and standard practices, terms, units, etc. is critical to understanding (and thus controlling) the process of producing good, predictable, and reproducible solid dosage forms.
Columnist Emil Ciurczak cautions that its time for the pharma industry to emphasize the P, and de-emphasize the A and the T in PAT
At a time when the amount of available data is increasing exponentially, why are we isolating ourselves from our brethren and the larger scientific community?
Loners make for fascinating drama, but theyll doom any process analytical technology (PAT) project. Triage and communication are essential, Ciurczak argues, and cross-functional trainings value can far exceed its costs.
Although PAT and technologies like NIR are important, there still are things that they cannot do, concedes NIR expert Emil Ciurczak. Are advocates within the industry suspending rational and much needed skepticism, he asks, when they talk about eliminating final product stability testing altogether?
cGMPS are essential, but when cGMP dogma triumphs over common sense and prevents innovation, were all in trouble, says NIR expert and pharmaceutical industry consultant, Emil Ciurczak. He offers some tips for drawing the line between compliance and absurdity.
NIR expert Emil Ciurczak thinks prosperity and the Internet are making today's graduates far too complacent and out of touch for their own good. Networking and professional societies are at risk, he says, and drug manufacturing will be worse off for it.
NIR expert Emil Ciurczak asks whether PAT will eliminate the need for traditional USP product release tests and concludes that theyre still essential as a reference method and important in minimizing liability.
Beware of process control software that is not PAT-specific, cautions Emil Ciurczak. He cites Excel, with its rounding errors, as a prime example of software written without the input of science-types.
PAT and analytical services dont always mix, as PAT columnist Emil Ciurczak relates. His advice: Dont allow your PAT group to become a stepchild. Ensure that it receives credit for PAT-based improvements.
NIR expert and Pharmaceutical Manufacturing columnist Emil Ciurczak discusses this year's conference in this downloadable audio file. For his article discussing highlights and key developments, see "IFPAC 2006 Under the Microscope."
"NIR person" and physical chemist Emil Ciurczak provides a thorough analysis of this year's IFPAC conference, held Feb. 21-23 in Arlington, Va.
Attention, corporate bean counters: PAT is not a magic bullet for reducing QC headcounts. In fact, it may require hiring more people, but the efforts will pay off in improved efficiencies and lower costs.
Emil Ciurczak reviews Decembers conference, which broke with tradition by focusing more on the business than the technical side of PAT.
Dont be penny-wise but pound-foolish during early planning and budgeting stages, and never base decisions on equipment sticker prices without considering savings in time to market.
Pharmaceutical processing & engineering: A consultant ponders the question, as it relates to NIR and pharmaceutical process analytical technology (PAT) projects that require a high level of hard-to-find technical expertise.
Pharmaceutical processing & engineering: Last year at the IFPAC conference, NIR guru Emil Ciurczak bemoaned the fact that PAT was being promoted by geeks for geeks. Now, however, he notes that an upcoming summit may lead the charge toward a new emphasis on convincing corporate and financial ...